Madopar HBS: Slow-Release Levodopa and Benserazide in Parkinsonian Patients Presenting Marked Fluctuations in Symptoms on Standard L-Dopa Treatment
- 1 January 1987
- journal article
- madopar hbs
- Published by S. Karger AG in European Neurology
- Vol. 27 (1) , 68-72
- https://doi.org/10.1159/000116195
Abstract
In this open study patients with advanced Parkinson’s disease, who experienced pronounced fluctuations in symptoms while on standard L-dopa, were switched from Mad-opar/Sinemet to Madopar HBS. The dosage was adjusted until optimal response was obtained. The effect was unsatisfactory in 4 cases and side effects intervened in another 2. The remaining 16 patients exhibited substantial and frequently significant improvements with regard to both akinetic and dyskinetic phenomena. L-Dopa dosage was increased in all cases, and addition of standard L-dopa was required in one third of the cases. These benefits continued in the majority of patients.Keywords
This publication has 0 references indexed in Scilit: